Aims/Background: We have previously reported that a new model of liver injury induced in mice by delayed-type hypersensitivity (DTH) to picryl chloride (PCI) mimicks the pathogenesis of human hepatitis. This liver injury is mediated by CD4(+) T cells. The interaction between lymphocyte function associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1) is an essential process for hepatocyte (HC) damage. The present study was undertaken to reveal the role of Th1 and Th2-like cytokines in regulating the liver injury. Methods. The kinetics of cytokine production were examined by ELISA and RT-PCR after the elicitation of liver injury for both serum protein and liver mRNA expression, respectively. A co-culture assay between liver nonparenchymal cells (NPC) and HC was conducted to evaluate the cytokine regulation on the cell-cell interaction. Expression of LFA-1 on NPC and ICAM-1 on HC were examined by FACScan and ELISA, respectively. Results: Serum IL-2 and IFN-gamma showed a peak production at 6 and 12 h, while IL-5 and IL-4 reached their maximum levels at Is and 24 h after induction of liver injury, respectively. Liver mRNA expression of IFN-gamma and IL-4 had a similar time course to their corresponding products. Both recombinant murine IFN-gamma and IL-2 triggered the hepatotoxicity of NPC or spleen cells at 0 h. In this case, an increased expression of both LFA-1 on NPC and ICAM-1 on HC was also observed. In contrast, IL-4 and IL-5 completely abolished the hepatotoxicity of NPC at 12 h without influencing the adhesion molecules. Conclusion: Th1 and Th2 may be involved in regulating liver injury. Th1/Th2 balance may critically contribute to the production of the liver injury or recovery from it.
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
Xu, Q
Wu, FH
论文数: 0引用数: 0
h-index: 0
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
Wu, FH
Jiang, JY
论文数: 0引用数: 0
h-index: 0
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
Jiang, JY
Lu, JF
论文数: 0引用数: 0
h-index: 0
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
Lu, JF
Chen, XC
论文数: 0引用数: 0
h-index: 0
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
Chen, XC
Zhang, BL
论文数: 0引用数: 0
h-index: 0
机构:
China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R ChinaChina Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210009, Peoples R China
机构:
Chiba Inst Sci, Fac Pharmaceut Sci, Lab Clin Pharm, Chiba 2880025, JapanChiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chuo Ku, Chiba 2608675, Japan
Masubuchi, Yasuhiro
Sugiyama, Shiori
论文数: 0引用数: 0
h-index: 0
机构:
Chiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chuo Ku, Chiba 2608675, JapanChiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chuo Ku, Chiba 2608675, Japan
Sugiyama, Shiori
Horie, Toshiharu
论文数: 0引用数: 0
h-index: 0
机构:
Chiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chuo Ku, Chiba 2608675, JapanChiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chuo Ku, Chiba 2608675, Japan